Characteristics of MF patients
| PID . | Diagnosis . | Stage . | Driver . | NGS . | PB blasts, % . | MIPSS70 . | MYSEC . | Therapy . | Follow-up . |
|---|---|---|---|---|---|---|---|---|---|
| 1 | PMF | Chronic | CALR | MPL | 1.5 | IM | — | INF | Alive (CP) |
| 2 | PMF | Chronic | CALR | ASXL1, U2AF1 | 1.5 | High | — | Rux | Alive (AP) |
| 3 | PMF | Accelerated | JAK2 | ASXL1 | 18.5 | High | — | Rux | Dead (post-allo) |
| 4 | PMF | Accelerated | None | ASXL1, NRAS, SETBP1, SRSF2 | 11 | High | — | Rux | Dead (AML) |
| 5 | PMF | Accelerated | JAK2 | ASXL1, KRAS, TET2, U2AF1 | 17.5 | High | — | Rux | Dead (AML) |
| 6 | PPV-MF | Chronic | JAK2 | ASXL1, SF3B1 | 8.5 | — | IM2 | Rux | Alive (CP) |
| 7 | PPV-MF | Chronic | JAK2 | SF3B1 | 13.5 | — | High | Rux* | Dead (AP) |
| 8 | PPV-MF | Accelerated | JAK2 | EZH2, PHF6 | 14 | — | High | Rux | Dead (BM failure) |
| 9 | PET-MF | Chronic | CALR | ASXL1, GATA2, TET2 | 0.5 | — | IM2 | Rux | Alive (CP) |
| 10 | PET-MF | Chronic | CALR | SF3B1 | 0.5 | — | Low | None | Alive (CP) |
| 11 | PET-MF | Chronic | CALR | TET2 | 0.5 | — | IM1 | ANA | Alive (CP) |
| 12 | PET-MF | Chronic | CALR | ASXL1 | 2 | — | IM1 | Rux | Alive (CP) |
| 13 | PET-MF | Chronic | JAK2 | ASXL1, RUNX1, SRSF2, TET2, TP53 | 6 | — | High | Rux | Dead (AP) |
| 14 | PET-MF | Accelerated | CALR | ASXL1, TET2 | 8 | — | IM1 | Rux | Alive (allo) |
| PID . | Diagnosis . | Stage . | Driver . | NGS . | PB blasts, % . | MIPSS70 . | MYSEC . | Therapy . | Follow-up . |
|---|---|---|---|---|---|---|---|---|---|
| 1 | PMF | Chronic | CALR | MPL | 1.5 | IM | — | INF | Alive (CP) |
| 2 | PMF | Chronic | CALR | ASXL1, U2AF1 | 1.5 | High | — | Rux | Alive (AP) |
| 3 | PMF | Accelerated | JAK2 | ASXL1 | 18.5 | High | — | Rux | Dead (post-allo) |
| 4 | PMF | Accelerated | None | ASXL1, NRAS, SETBP1, SRSF2 | 11 | High | — | Rux | Dead (AML) |
| 5 | PMF | Accelerated | JAK2 | ASXL1, KRAS, TET2, U2AF1 | 17.5 | High | — | Rux | Dead (AML) |
| 6 | PPV-MF | Chronic | JAK2 | ASXL1, SF3B1 | 8.5 | — | IM2 | Rux | Alive (CP) |
| 7 | PPV-MF | Chronic | JAK2 | SF3B1 | 13.5 | — | High | Rux* | Dead (AP) |
| 8 | PPV-MF | Accelerated | JAK2 | EZH2, PHF6 | 14 | — | High | Rux | Dead (BM failure) |
| 9 | PET-MF | Chronic | CALR | ASXL1, GATA2, TET2 | 0.5 | — | IM2 | Rux | Alive (CP) |
| 10 | PET-MF | Chronic | CALR | SF3B1 | 0.5 | — | Low | None | Alive (CP) |
| 11 | PET-MF | Chronic | CALR | TET2 | 0.5 | — | IM1 | ANA | Alive (CP) |
| 12 | PET-MF | Chronic | CALR | ASXL1 | 2 | — | IM1 | Rux | Alive (CP) |
| 13 | PET-MF | Chronic | JAK2 | ASXL1, RUNX1, SRSF2, TET2, TP53 | 6 | — | High | Rux | Dead (AP) |
| 14 | PET-MF | Accelerated | CALR | ASXL1, TET2 | 8 | — | IM1 | Rux | Alive (allo) |
Allo, allo-HSCT; AML, acute myeloid leukemia; ANA, anagrelide; AP, accelerated phase; CP, chronic phase; IM, intermediate; INF, pegylated interferon α-2a; MIPSS70, mutation-enhanced international prognostic scoring system for PMF; MYSEC, MF secondary to PV and ET-prognostic model; NGS, next-generation sequencing performed on whole PB or BM; PET-MF, post–essential thrombocythemia MF; PID, patient identification number; PMF, primary MF; PPV-MF, post–polycythemia vera MF.
Treatment was stopped before sampling.